March 27, 2015 by Brad Perriello
Kips Bay Medical turned to founder, chairman & CEO Manny Villafaña and other backers for a private placement worth up to $3.25 million, as the company makes a last-ditch bid to get its eSVS surgical mesh on the market.
The eSVS mesh is designed to keep vein grafts open during in coronary artery bypass graft surgeries. The device is comprised of a flexible, knitted sleeve that fits around the outside of the vein in order to reduce vessel wall stress and mitigate the potential for vessel injury. Read more
March 30, 2015 by Mark Hollmer
Stealthy Saphena Medical reported raising close to half of a $3 million planned offering toward development of a device designed to harvest veins for coronary artery bypass grafting.
The West Bridgewater, Mass.-based startup disclosed in a recent SEC filing that it has pulled in nearly $1.27 million so far, through the sale of Series B preferred stock. Read more
April 2, 2015 by Brad Perriello
Gelesis just last week drummed up a $22 million funding round, but that’s not stopping the Boston-based company from registering for an initial public offering worth $60 million.
Gelesis, which makes an anti-obesity pill using a super-absorbent hydrogel to induce feelings of satiety, said the Gelesis100 pill is also designed to improve glycemic control. The company expects to launch the product in the U.S. in 2019, assuming it wins FDA approval. Gelesis100 could hit the European market a year earlier, the company said. Read more